StreetAlpha.app
Home › Stocks › ANRO

Alto Neuroscience, Inc. (ANRO)

Healthcare
$25.37
▼ −4.30%
LAST CLOSE · NOV 20

Alto Neuroscience develops drug candidates for psychiatric disorders, using biomarkers found through data analytics to select patients. It last closed at $25.37 on Nov 20, down 4.30% on the day. The next earnings report for ANRO is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, ANRO reported EPS of -$0.54. Over its last 8 reports the stock moved an average of 7.3% the session after earnings. Over the last 12 months ANRO insiders bought $0 of stock on the open market and sold $5.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is ANRO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANRO.

Key Stats

Last 12 months
Results
Net income
−$95.2M
EPS (diluted)
−$2.32
Free cash flow
−$79.7M
Valuation
Market cap
$1.0B
40.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$319.3M
At Sep 30
Debt
$13.5M
At Sep 30
Shareholder equity
$296.5M
Shares outstanding
40.1M
At Nov 5
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2023: −$36.3M−$36.3MFY2023FY2024: −$61.4M−$61.4MFY2024FY2025: −$63.2M−$63.2MFY2025

From ANRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
-$0.54
Quarter ended Sep 2026
Year ago EPS
-$0.52
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.56Dec '24Mar 2025: -$0.56Mar '25Jun 2025: -$0.65Jun '25Sep 2025: -$0.52Sep '25Dec 2025: -$0.45Dec '25Mar 2026: -$0.80Mar '26Jun 2026: -$0.65Jun '26Sep 2026: -$0.54Sep '26Latest -$0.54
Revenue by quarter
Not enough quarters on file yet.
How ANRO moved after its last 8 reports
Average move the session after a report ±7.3%
Nov 10, 2026After the close+8.9%
Aug 12, 2026After the close+10.7%
Jul 13, 2026Time not announced+5.8%
May 13, 2026Time not announced−7.2%
Mar 16, 2026Time not announced+9.1%
Nov 12, 2025Time not announced+6.0%
Aug 13, 2025After the close−0.3%
May 14, 2025After the close+10.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ANROStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANRO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANRO

Technical Analysis

ANRO · as of the Nov 20 close · updated each morning
Uptrend

The stock is 0% below its 20 day and 1% below its 50 day average. It is 1% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 49). The nearest support is the 200 day average at $25.00, and the nearest resistance the Pivot at $25.42.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 8.2%/day
Key levels
$37.4852 week high+47.7%
$28.30Swing high (Jun 30)+11.5%
$28.02100 day average+10.4%
$26.43Pivot R1+4.2%
$25.5850 day average+0.8%
$25.42Pivot+0.2%
$25.3720 day average+0.0%
$25.37Last close
$25.00200 day average−1.5%
$24.35Pivot S1−4.0%
$24.30Swing low (Jul 7)−4.2%
$12.5152 week low−50.7%
Indicators
RSI (14)48.54Middle of its rangeNeutral
MACD0.50Above its signal lineBullish
Stochastic36.3Middle of its rangeNeutral
ADX (14)24.3Weak trend
Williams %R-69.7Oversold below −80, overbought above −20Neutral
CCI (20)1.7Oversold below −100, overbought above 100Neutral
Rate of change+0.8%Change over 10 sessionsBullish
ATR (14)$2.08Typical daily range, 8.2% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for ANRO

What happened before

See how ANRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for ANROHow many large options trades hit ANRO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 32 selling
  • ▲Held by funds +23.6 pts
  • ▲Funds holding +19
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding133114+16.7%
In funds' top 1074+75.0%
Held by funds97.1%73.5%+23.6 pts
New / increased27 / 6627 / 39+40.9%
Reduced / sold out22 / 1026 / 22−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANRO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$5.6M2 sales · 2 insiders
2026-09 sold $3.6M2026-11 sold $2.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Jr. Michael Conick HanleyCOOSale75,000$27.61$2.1M
Sep 30Nicholas Conrad SmithPresident And CFOSale134,886$26.45$3.6M
Every insider buy and sale for ANRO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANRO insider trades →

From SEC Form 4 filings by ANRO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANRO is in one of them and how their past ANRO trades turned out.

ANRO in the AI portfolios
Loading…

ANRO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANRO in an article yet. Here's the latest on the wider market.

ANRO in the news

About Alto Neuroscience

Alto Neuroscience is a pharmaceutical company based in Mountain View, California, that develops drugs for psychiatric disorders. It uses data analytics and machine learning to find biomarkers that can help identify which patients are most likely to benefit from a given treatment. The company is developing its product candidates for conditions including major depressive disorder and schizophrenia, and it has not yet commercialized a drug. Its work is aimed at patients with these conditions and the clinicians who treat them.

Headquarters
Mountain View, CA